Characterizing Breast Cancer With 18F-FES PET/CT
- Conditions
- Breast Cancer
- Interventions
- Diagnostic Test: 18F-FES PET/CT scan
- Registration Number
- NCT05613270
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
18F-fluoroestradiol (FES) is radioactive labeled estradiol, developed for in vivo visualization of estrogen receptor (ER) using positron emission tomography (PET). In this prospective study, 18F-FES PET/CT will be used to evaluate ER activity of metastatic disease and their potential sensitivity to endocrine therapy in ER-positive breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 50
- suspected or confirmed metastatic ER-positive breast cancer;
- 18F-FDG PET/CT within two weeks;
- signed written consent.
- pregnancy;
- breastfeeding;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 18F-FES PET/CT 18F-FES PET/CT scan Inject 18F-FES and then perform PET/CT scan.
- Primary Outcome Measures
Name Time Method Lesions detected by 18F-FES PET/CT through study completion, an average of 1 year The number of target lesions was calculated by 18F-FES PET/CT.
Compared with 18F-FDG PET/CT through study completion, an average of 1 year The number of lesions detected by 18F-FES PET/CT was compared with 18F-FDG PET/CT.
Standardized uptake value of 18F-FES in BC through study completion, an average of 1 year The max standard uptake value (SUVmax) was measured in the breast cancer lesions on 18F-FES PET/CT.
- Secondary Outcome Measures
Name Time Method Overall survival 3 years Evaluate overall survival (OS) in patients receiving regimens containing endocrine therapy
Trial Locations
- Locations (1)
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China